|

Abiraterone Clinical Trials

20 actively recruiting trials across 19 locations

▲ +1 trial since May 2026

Also known as: 154229-19-3, 16-dien-3beta-ol, 17-(3-Pyridyl)androsta-5, Abiraterone acetate, CB 7598 +3 more

Pipeline

Phase 1: 4Phase 2: 7Phase 3: 5Phase 1/2: 4

Top Sponsors

  • Novartis Pharmaceuticals4
  • Amgen2
  • University of Washington1
  • University of Nebraska1
  • University of California, Davis1

Indications

  • Cancer20
  • Metastatic Castration-resistant Prostate Cancer4
  • Prostate Cancer3
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)2
  • Stage IV Prostate Cancer AJCC v82

San Francisco, California2 trials

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

UCSF

Phase 2
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

University of California San Francisco

Phase 1

Birmingham, Alabama1 trial

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Central Alabama Research

Phase 3

Dothan, Alabama1 trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Site

Phase 3

Anchorage, Alaska1 trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Anchorage Associates in Radiation Medicine

Phase 3

Gilbert, Arizona1 trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona1 trial

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic in Arizona

Phase 2

Tucson, Arizona1 trial

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 111

Phase 1/2

Duarte, California1 trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

City of Hope National Medical Center

Phase 1

La Jolla, California1 trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

University of California San Diego - Moores Cancer Center

Phase 2

Los Angeles, California1 trial

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

UCLA Hematology & Oncology ( Site 0003)

Phase 1/2

Orange, California1 trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Chao Family Comprehensive Cancer Centre

Phase 3

Sacramento, California1 trial

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

University of California Davis Comprehensive Cancer Center

Phase 2

New Haven, Connecticut1 trial

SNV1521 in Participants With Advanced Solid Tumors

Smilow Cancer Hospital at Yale New Haven

Phase 1

Tampa, Florida1 trial

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Moffitt Cancer Center

Phase 2

Iowa City, Iowa1 trial

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Uni Of Iowa Hospitals And Clinics

Phase 1/2

Omaha, Nebraska1 trial

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

University of Nebraska Medical Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Pittsburgh Cancer Institute (UPCI)

Phase 2

Dallas, Texas1 trial

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Mary Crowley Cancer Research

Phase 1

El Paso, Texas1 trial

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Rio Grande Urology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.